Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sercan Ön

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Chemotherapy (Florence, Italy)|May 29, 2025
Efficacy of pembrolizumab in patients with chemotherapy-resistant gestational trophoblastic neoplasia, a case reportSercan Ön
Turkish Thoracic Journal|July 18, 2022
Evaluation of Treatment Efficacy of Tyrosine Kinase Inhibitors in Rare Single EGFR Exon 21 L861Q Mutation: Single Center ExperiencePınar Gürsoy, Burcu Çakar, Sercan Ön, et al.
Melanoma Research|June 25, 2022
Immunotherapy-induced granulomatous reaction in patients with melanomaHalil Taskaynatan, Damla Gunenc, Sercan Ön, et al.
Balkan Medical Journal|April 4, 2024
Guillain-Barre Syndrome due to Adjuvant Therapy with Dabrafenib Plus TrametinibAslı Geçgel, Sercan Ön, Yeliz Çiftçi, et al.
Expert Review of Clinical Immunology|June 3, 2026
Seasonal timing of anti-PD-1 therapy and survival outcomes in a real-world Pan-Cancer CohortHaydar C Yüksel, Caner Acar, Gokhan Şahin, et al.
Scientific Reports|February 25, 2026
DUSP29 does not regulate melanoma-myoblast interactions in a skeletal muscle co-culture modelSercan Ön, Harika Atmaca İlhan, Damla Günenç, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Trabectedin for L-Type Sarcoma: A Retrospective Multicenter StudySercan Ön, Barış Köksal, Zafer Arık, et al.
Cancers|March 28, 2026
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG)Bengü Dursun, Şendağ Yaslıkaya, Serhat Sekmek, et al.
Breast (Edinburgh, Scotland)|October 8, 2022
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter studyHasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabiyev, et al.
Journal of Geriatric Oncology|September 8, 2023
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG studyOkan Avcı, Yakup İriağaç, Eyyüp Çavdar, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Chemotherapy (Florence, Italy)|May 29, 2025
Efficacy of pembrolizumab in patients with chemotherapy-resistant gestational trophoblastic neoplasia, a case reportSercan Ön
Turkish Thoracic Journal|July 18, 2022
Evaluation of Treatment Efficacy of Tyrosine Kinase Inhibitors in Rare Single EGFR Exon 21 L861Q Mutation: Single Center ExperiencePınar Gürsoy, Burcu Çakar, Sercan Ön, et al.
Melanoma Research|June 25, 2022
Immunotherapy-induced granulomatous reaction in patients with melanomaHalil Taskaynatan, Damla Gunenc, Sercan Ön, et al.
Balkan Medical Journal|April 4, 2024
Guillain-Barre Syndrome due to Adjuvant Therapy with Dabrafenib Plus TrametinibAslı Geçgel, Sercan Ön, Yeliz Çiftçi, et al.
Expert Review of Clinical Immunology|June 3, 2026
Seasonal timing of anti-PD-1 therapy and survival outcomes in a real-world Pan-Cancer CohortHaydar C Yüksel, Caner Acar, Gokhan Şahin, et al.
Scientific Reports|February 25, 2026
DUSP29 does not regulate melanoma-myoblast interactions in a skeletal muscle co-culture modelSercan Ön, Harika Atmaca İlhan, Damla Günenç, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Trabectedin for L-Type Sarcoma: A Retrospective Multicenter StudySercan Ön, Barış Köksal, Zafer Arık, et al.
Cancers|March 28, 2026
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG)Bengü Dursun, Şendağ Yaslıkaya, Serhat Sekmek, et al.
Breast (Edinburgh, Scotland)|October 8, 2022
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter studyHasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabiyev, et al.
Journal of Geriatric Oncology|September 8, 2023
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG studyOkan Avcı, Yakup İriağaç, Eyyüp Çavdar, et al.
Pageof 2